The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial
Open accessAbstract
RATIONALE: Antibiotic therapy for early Pseudomonas aeruginosa infection in patients with cystic fibrosis (CF) is effective, but the optimal therapeutic regimen and duration for early treatment remains unclear. The EarLy Inhaled Tobramycin for Eradication (ELITE) study was designed to assess the efficacy and safety of two regimens (28 and 56 days) of tobramycin inhalation solution (TIS) 300 mg/5 ml twice daily for the treatment of early onset P aeruginosa infection in patients with CF. METHODS: In this open-label randomised multicentre study, patients with CF (aged > or = 6 months) with early P aeruginosa infection were treated for 28 days with TIS twice daily administered by the PARI LC PLUS (PARI GmbH, Starnberg, Germany) jet nebuliser. After 28 days, patients were randomised 1:1 to either stop TIS (n=45) or to receive a further 28 days of TIS (n=43). The primary endpoint was the median time to recurrence of P aeruginosa (any strain). Secondary endpoints included the proportion of patients free of P aeruginosa infection 1 month after cessation of therapy and safety assessments. RESULTS: The median time to recurrence of P aeruginosa (any strain) was similar between the two groups. In total, 93% and 92% of the patients were free of P aeruginosa infection 1 month after the end of treatment and 66% and 69% remained free at the final visit in the 28-day and 56-day groups, respectively. TIS was well tolerated. CONCLUSIONS: Treatment with TIS for 28 days is an effective and well tolerated therapy for early P aeruginosa infection in patients with CF. TRIAL REGISTRATION NUMBER: NCT00391976.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., & Gibson, R. L. (2002) · Pediatric Pulmonology · doi:10.1002/ppul.10127 · Cited by 1,007
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus
Döring, G., Conway, S. P., Heijerman, H. G. M., Hodson, M. E., Høiby, N., Smyth, A., Touw, D. J., & the Consensus Committee, F. (2000) · European Respiratory Journal · doi:10.1034/j.1399-3003.2000.16d30.x · Cited by 620
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
Valerius, N. H., Koch, C., & Høiby, N. (1991) · The Lancet · doi:10.1016/0140-6736(91)91446-2 · Cited by 475
Frederiksen, B., Koch, C., & Høiby, N. (1997) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(199705)23:5<330::aid-ppul4>3.0.co;2-o · Cited by 473
Kosorok, M. R., Zeng, L., West, S. E. H., Rock, M. J., Splaingard, M. L., Laxova, A., Green, C. G., Collins, J., & Farrell, P. M. (2001) · Pediatric Pulmonology · doi:10.1002/ppul.2009.abs · Cited by 400
Extracellular Toxins of Pseudomonas aeruginosa
Liu, P. V. (1974) · Journal of Infectious Diseases · doi:10.1093/infdis/130.supplement.s94 · Cited by 373
Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis
Gibson, R. L., Emerson, J., McNamara, S., Burns, J. L., Rosenfeld, M., Yunker, A., Hamblett, N., Accurso, F., Dovey, M., Hiatt, P., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-855oc · Cited by 318
Early intervention and prevention of lung disease in cystic fibrosis: a European consensus
Döring, G., & Hoiby, N. (2004) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2004.03.008 · Cited by 304
Ratjen, F., Döring, G., & Nikolaizik, W. H. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06124-4 · Cited by 218
Self-citationHansen, C. R., Pressler, T., & Høiby, N. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.06.009 · Cited by 214
Cited by
Elborn, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00576-6 · Cited by 1,805
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update
Reynolds, D., & Kollef, M. (2021) · Drugs · doi:10.1007/s40265-021-01635-6 · Cited by 721
Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis
Hauser, A. R., Jain, M., Bar-Meir, M., & McColley, S. A. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-10 · Cited by 411
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Langton Hewer, S. C., & Smyth, A. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004197.pub4 · Cited by 324
Factors associated with FEV1decline in cystic fibrosis: analysis of the ECFS Patient Registry
Kerem, E., Viviani, L., Zolin, A., MacNeill, S., Hatziagorou, E., Ellemunter, H., Drevinek, P., Gulmans, V., Krivec, U., & Olesen, H. (2014) · European Respiratory Journal · doi:10.1183/09031936.00166412 · Cited by 296
Metadata
- Authors
- Ratjen, F., Munck, A., Kho, P., Angyalosi, G., & for the ELITE Study Group
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2009-12-08
- Volume
- 65
- Issue
- 4
- Pages
- 286-291
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2142641193
- Cited by
- 291
- References
- 17
- FWCI
- 17.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. https://app.cochat.ai/papers/10.1136/thx.2009.121657
- The paper
- Ratjen, F., Munck, A., Kho, P., Angyalosi, G., & for the ELITE Study Group. (2010). Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. https://doi.org/10.1136/thx.2009.121657
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.